Medivir Raises SEK 45 Million in Premium Directed Share Issue to Fund New Rare-Disease Program

Medivir AB ( (SE:MVIR) ) has provided an update.

Medivir has resolved to carry out a directed share issue of 90 million new ordinary shares, raising SEK 45 million from Carl Bennet AB at a 19% premium to the latest closing price, in a move that brings a financially strong, long-term owner into its shareholder base. The capital injection is earmarked for the clinical development of MIV-711 in Osteogenesis Imperfecta, a new and strategically important indication that the board believes could offer market potential on par with flagship candidate Fostrox, while the choice of a directed issue over another rights issue is aimed at securing funds quickly and cost‑effectively, avoiding discounts and guarantee costs and strengthening Medivir’s hand in future partnership and out-licensing negotiations.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Sweden-based pharmaceutical development company listed on Nasdaq Stockholm, focused on innovative treatments for diseases with significant unmet medical needs. Its pipeline includes candidates such as Fostrox for primary liver cancer and MIV-711, which recently received Orphan Drug Designation from the U.S. FDA for the treatment of Osteogenesis Imperfecta, positioning the company in niche, high-value therapeutic areas.

Average Trading Volume: 1,313,379

Technical Sentiment Signal: Sell

Current Market Cap: SEK200.5M

Learn more about MVIR stock on TipRanks’ Stock Analysis page.